A startup built an app to help people with type 2 diabetes better control their glucose levels

pulse

May 1, 2017 4:53 PM

Amalgam Rx, founded by digital therapeutic veterans and siblings Ryan Sysko and Dr. Suzanne Clough launched their first app on Monday.

A new startup called Amalgam Rx wants to change the way people with type 2 diabetes manage their insulin intake with the help of a prescription app.

There are roughly 30 million people in the US living with diabetes, many of whom inject insulin, a hormone that's produced in healthy bodies to control blood sugar levels. For many people living with diabetes — including the 1.25 million people in the US who have Type-1 diabetes — injecting insulin is part of the daily routine.

In particular, it's the group of people who have type 2 and are just starting to use insulin that the startup, founded by a pair of siblings who also founded another digital therapeutics company WellDoc, wants to help.

Ryan Sysko, Amalgam Rx CEO, told Business Insider that when a patient starts using insulin, the doctor often prescribes a low dose to see how their body reacts. A patient might stay on that dose, which could be too low to really do anything, until their next visit. Instead, Sysko, along with his sister, Amalgam's chief medical officer Dr. Suzanne Clough, developed an algorithm to help people increase their insulin doses as needed.

The FDA-cleared, prescription iSage Rx app launched on Monday.

Heres how it works

The goal, Sysko said, is to use the app to accelerate the process of getting blood sugar levels into the target healthy range, which is a key part of managing diabetes.

Amalgam Rx's iSage Rx app is one of a few so-called "insulin titration" apps out there, and it's part of a growing movement to use software to treat diseases alongside (or occasionally instead of) traditional methods.

Eventually, Amalgam Rx wants to expand beyond diabetes to other disease areas, ideally partnering with pharmaceutical companies to create app-medication combinations. So far, the company's raised less than $1 million in seed funding.

pulse